FDA Approves Ionis' Zanvastro as the First Treatment for Alexander Disease

The FDA approved Ionis Pharmaceuticals’ Zanvastro (zilganersen) injection for Alexander disease in pediatric and adult patients, roughly 19 days ahead of the drug’s September 22 PDUFA date. It is the first FDA-approved treatment for the ultra-rare, progressive, and often fatal neurological disorder, and the first therapy that directly targets the GFAP protein buildup that drives the disease.

The approval

Alexander disease affects fewer than 1 in a million people and is caused by mutations in the GFAP gene. The abnormal protein accumulates in astrocytes, the brain’s support cells, and leads to seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain. Until now, care was limited to supportive measures.

Zanvastro is an antisense oligonucleotide that cuts production of the abnormal GFAP protein. It is injected into the spinal canal every three months by a trained professional.

The FDA based the approval on a randomized controlled study (NCT04849741) of 49 patients aged 2 and older, plus a 4-patient substudy under age 2. Because the disease spans a wide age range and a conventional large trial is impossible for a condition this rare, the agency used a tiered evidence standard. Patients aged 5 and older with walking difficulty at baseline showed better walking speed at 61 weeks than the untreated comparison. In children aged 2 to 4, where walking speed is unreliable, a broader motor-skills measure covering standing, walking, running, and jumping improved while the control group declined. For infants under 2, pharmacokinetic modeling plus safety data from the four youngest patients supported the indication.

The most common side effects were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis has been reported, and the label tells patients and caregivers to watch for symptoms.

Why it matters

The approval validates Ionis’ antisense platform in a fourth neurology indication, after Spinraza (SMA), Wainua (ATTRv-PN), and Tryngolza (FCS). It also carries commercial and strategic weight beyond the disease itself.

Ionis will launch Zanvastro independently in the US, its first wholly owned neurology launch, and licensed ex-US rights to Recordati in June for a $30 million upfront payment plus milestones and tiered royalties up to the mid-20% range.

The approval also earns Ionis a Rare Pediatric Disease Priority Review Voucher, a transferable asset typically worth roughly $100 million or more that the company can sell or use to speed a future filing.

The market’s verdict

Investors treated the approval as already priced in. IONS shares fell about 5.2% Thursday to $58.13, giving Ionis a market value near $9.7 billion. The pattern matches the pre-FDA platform analysis: at $300,000 to $2 million per patient per year, Zanvastro’s ultra-rare addressable revenue does not by itself move a near-$10 billion market cap. The thesis is platform validation, and the next catalyst matters more than the launch.

What to watch

The next binary event is bepirovirsen, Ionis’ hepatitis B candidate partnered with GSK, which has an October 26 PDUFA date. A bepirovirsen approval would deliver the first functional-cure therapy for chronic HBV and a far larger commercial opportunity than Zanvastro. Watch also for whether Ionis sells the priority review voucher and for initial US launch execution.